References: Approach to antidepressant therapy for major depression in adults and young people
Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hebert C, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009;19(7):457–65. https://www.ncbi.nlm.nih.gov/pubmed/19345072
Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167(3):281–8. https://www.ncbi.nlm.nih.gov/pubmed/20008946
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391(10128):1357–66. https://www.ncbi.nlm.nih.gov/pubmed/29477251
Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737. https://www.ncbi.nlm.nih.gov/pubmed/20940209
Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 2019;6(7):601–9. https://www.ncbi.nlm.nih.gov/pubmed/31178367
Giorlando F, Teister J, Dodd S, Udina M, Berk M. Hyponatraemia: an audit of aged psychiatry patients taking SSRIs and SNRIs. Curr Drug Saf 2013;8(3):175–80. https://www.ncbi.nlm.nih.gov/pubmed/23841535
Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, et al. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess 2018;22(63):1–136. https://www.ncbi.nlm.nih.gov/pubmed/30468145
Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320. https://www.ncbi.nlm.nih.gov/pubmed/26376805
Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49(12):1087–206. https://www.ncbi.nlm.nih.gov/pubmed/26643054
Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008;16(7):558–67. https://www.ncbi.nlm.nih.gov/pubmed/18591576
Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168(7):689–701. https://www.ncbi.nlm.nih.gov/pubmed/21536692
Shin JY, Park MJ, Lee SH, Choi SH, Kim MH, Choi NK, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ 2015;351:h3517. https://www.ncbi.nlm.nih.gov/pubmed/26173947
Sultana J, Spina E, Trifiro G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol 2015;11(6):883–92. https://www.ncbi.nlm.nih.gov/pubmed/25736834
